thEsE ArE tough timEs For wAl-mArt,AmEriCA’s BiggEst rEtAilEr. long ACCusED oF{{u}} (1) {{/u}}smAll-townAmEriCA mAD ConDEmnED For thE sElFishnEss oF its pAy, thE CompAny hAs lAtEly ComE unDEr{{u}} (2) {{/u}}For its mEAnnEss ovEr EmployEEs’ hEAlth-CArE BEnEFits. thE ChArgE is ArguABly{{u}} (3) {{/u}}: thE Firm’s hEAlth CovErAgE, whilE{{u}} (4) {{/u}}lEss ExtEnsivE thAn thE AvErAgE For Big CompAniEs, is on EquAl tErms{{u}} (5) {{/u}}othEr rEtAilErs’.But BAD puBliCity, CouplED with rising Costs, hAs{{u}} (6) {{/u}}thEBEntonvillE giAnt to ACtion. wAlmArt is mAking ChAngEs thAt shoulD shiFt thE grounD inAmEriCA’s hEAlthCArE DEBAtE. onE{{u}} (7) {{/u}}is to rEDuCE thE priCEs oF mAny gEnEriC, or out-oF-pAtEnt, prEsCription Drugs. wAl-mArt’s CritiCs Dismiss thE movE As A puBliCity{{u}} (8) {{/u}}. thE list oF Drugs inCluDEs only 143 DiFFErEnt mEDiCinEs AnD ExCluDEs mAny populAr group. truE, But short-sightED、wAl-mArt hAs{{u}} (9) {{/u}}rEtAiling By using its sizE to squEEzE suppliErs AnD{{u}} (10) {{/u}}thE gAins on to ConsumErs. it CoulD{{u}} (11) {{/u}}thE sAmE with Drugs.A、"wAl-mArt EFFECt" in Drugs will not solvEAmEriCA’s hEAlth-Costs proBlEm: group ACCount For only A smAll shArE oF Drug Costs, whiCh in turn mAkE{{u}} (12) {{/u}}only 10% oF ovErAll hEAlth spEnDing.But it woulD{{u}} (13) {{/u}}. thE Firm’s othEr initiAtivE is morE{{u}} (14) {{/u}}. wAl-mArt is joining thE smAll But FAst-growing group oF EmployErs{{u}} (15) {{/u}}ArE Controlling Costs By shiFting to hEAlth insurAnCE with high DEDuCtiBlEs. EArly EviDEnCE{{u}} (16) {{/u}}thEsE plAns Do hElp Firms Control thE Cost oF hEAlth insurAnCE.But CritiCs sAy thAt thE sAvings ArE{{u}} (17) {{/u}}. thEy ArguE thAt thE plAns shiFt Costs to siCkEr workErs, DisCourAgE prEvEntAtivE CArE AnD will AnywAy Do littlE to{{u}} (18) {{/u}}ovErAll hEAlth spEnDing, {{u}} (19) {{/u}}most oF thE $2 trillion thAtAmEriCA{{u}} (20) {{/u}}hEAlth CArE EACh yEAr goEs to pEoplE with multiplE ChroniC DisEAsEs.

A．sinCE
B．thEn
C．whEn
D．BECAusE oF